In April, The New York Times proclaimed that a gen-AI-driven company that hawked compounded GLP-1 drugs was potentially on track to have $1.8 billion in 2026 sales. The paper also reported that the company, MEDVi, had generated $401 million in sales in 2025, saying it had been given access to unspecified company financials. By then,…
What if psilocybin works about as well for depression as an SSRI?
For all the hope invested in them as treatments for depression, classic psychedelics may end up offering only incremental gains for most patients, based on some of the most recent data in the field. If that thesis proves true, the arc of psilocybin, the most widely studied psychedelic of late, would broadly echo the trajectory…
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, fatty liver disease and its more serious inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), were often overlooked conditions with few approved treatments. Boehringer Ingelheim is among the companies now going after them with a concerted push. “We have a program in MASH, in the liver, the LIVERAGE program, plus a robust data-generation program to…
Blazing new paths for biotech
For the past several years, success has grown more elusive for American biotech firms. Even in the more robust investment climates prior to 2022, developing and growing a biotech always required a combination of risk appetite and patient capital that did not lend itself to the rapid exits typical of other areas of tech investing. …
Immunai’s digital ‘plumbing’ keeps AstraZeneca coming back
Immunai, a startup building a foundation model of the human immune system, has expanded its oncology collaboration with AstraZeneca for the third time. Immunai is eligible to receive up to $37.5 million over 2026 and 2027 under the new agreement, which extends its AMICA-OS platform deeper into AstraZeneca’s clinical development pipeline. The two companies began…
Lilly’s triple agonist delivers up to 71.2 lbs of weight loss in Phase 3 trial
Lilly announced results from its Phase 3 TRIUMPH-4 trial of retatrutide, a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, on Thursday. In the efficacy-estimand analysis, participants taking the highest dose (12 mg) lost an average of 28.7% of their body weight at 68 weeks, about 71.2 pounds from a baseline of 248.5 pounds.…
Demystifying deep learning: An accessible introduction to neural networks in health research and epidemiology
As machine learning and deep learning technologies advance thanks to advances in computation, algorithms and data availability, the possibilities of the technology continue to expand in medicine. While these AI-driven approaches have real potential, such systems demand large volumes of representative data, careful privacy and security scrutiny and thoughtful long-term strategic planning. In this Q&A, Kathryn…






